CASI
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- CASI Pharmaceuticals announces safety monitoring committee recommendation to escalate CID-103 dose to next cohort in Phase 1 immune thrombocytopenia studySep 8, 2025
- CASI Pharmaceuticals announces FDA clearance of IND application for CID-103 in renal allograft antibody-mediated rejection (AMR)Aug 4, 2025